Nutriband Inc. has expanded its intellectual property portfolio with key patent and trademark developments, reinforcing its strategic position in the abuse-deterrent pharmaceutical delivery market. The company recently received a trademark registration from the U.S. Patent and Trademark Office for its brand name and secured a new patent in Macao for its AVERSA transdermal system.
The intellectual property milestones signal significant progress for Nutriband's innovative drug delivery platform. The AVERSA system is specifically designed to mitigate risks associated with potent drugs like fentanyl, including potential abuse, unauthorized diversion, and accidental exposure. With patents now granted in 46 countries, the company is building a robust defensive strategy to protect its technological advancements.
The AVERSA platform represents a potentially substantial market opportunity, targeting an estimated $80 million to $200 million in U.S. sales as the first abuse-deterrent opioid patch. This positioning could address critical public health concerns surrounding opioid misuse while providing a technological solution for safer pharmaceutical delivery.
Complementing its intellectual property strategy, Nutriband has also established a strategic partnership with Charlotte FC, which will enhance the company's brand visibility and community engagement. This multifaceted approach demonstrates Nutriband's commitment to innovation, market protection, and broader societal impact in the pharmaceutical technology sector.
